Skip to main content
Finanzoo GmbHFinanzoo GmbH

ADMA Biologics Value Stock - Dividend - Research Selection

Adma biologics

ISIN: US0008991046 , WKN: A12FAG

Market price date:
Market price:  

Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!

How our site works ...

✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month 
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.


DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet

Description of the company

ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company distributes its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,

NEWS


Adma Biologics (ADMA) Is Considered a Good Investment by Brokers: Is That True?

2023-11-22
The average brokerage recommendation (ABR) for Adma Biologics (ADMA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Yahoo

Is Aurinia Pharmaceuticals (AUPH) Stock Outpacing Its Medical Peers This Year?

2023-11-20
Here is how Aurinia Pharmaceuticals (AUPH) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
Yahoo

Why Adma Biologics Stock Crushed the Market on Friday

2023-11-17
Adma Biologics (NASDAQ: ADMA) finished the trading week on a high note, with its shares racing more than 4% higher in price on Friday. Investors were happy about the specialty healthcare company's latest news about its growing network of plasma-collection facilities throughout the country. Adma stock's rise easily topped the slight (0.1%) increase of the S&P 500 index on the day.
Yahoo

Analysts Offer Insights on Healthcare Companies: Cybin (CYBN), ADMA Biologics (ADMA) and Halozyme (HALO)

2023-11-17
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.
TipRanks

ADMA BioCenters Receives FDA Approval for its Tenth Plasma Collection Center, Located in Laurel, MD

2023-11-16
FDA Approval Signifies the Accomplishment of ADMA’s Corporate Goal of Plasma Supply Self-SufficiencyRAMSEY, N.J. and BOCA RATON, Fla. and LAUREL, Md., Nov. 16, 2023 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it has received U.S. Food and Drug Administration (“FDA”) approval for its tenth ADMA BioCe
Yahoo

ADMA Biologics wins FDA nod for tenth plasma collection center

2023-11-16
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.
Seeking Alpha

ADMA Biologics receives FDA approval for tenth plasma collection cent er

2023-11-16
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.
Thefly.com

ADMA Biologics, Inc. (NASDAQ:ADMA) Q3 2023 Earnings Call Transcript

2023-11-10
ADMA Biologics, Inc. (NASDAQ:ADMA) Q3 2023 Earnings Call Transcript November 8, 2023 ADMA Biologics, Inc. beats earnings expectations. Reported EPS is $0.01, expectations were $-0.01. Operator: Good afternoon, and welcome to the ADMA Biologics Third Quarter 2023 Financial Results and Corporate Update Conference Call on Wednesday, November 8, 2023. At this time, all participants are […]
Yahoo

ADMA Biologics: Strong Growth, Profitability Prospects and Buy Rating Affirmation – An In-depth Analysis

2023-11-10
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.
TipRanks

Why Adma Biologics Was Trouncing the Market Today

2023-11-09
Adma Biologics (NASDAQ: ADMA) stock experienced a nice pop in Thursday's trading session, after the company unveiled its latest set of quarterly earnings after market hours the previous day. Adma, which focuses on developing and marketing plasma-derived biologics, published third-quarter results showing that its total revenue topped $67 million. It also meant a double beat for Adma, as analysts tracking the stock were anticipating slightly over $62 million in revenue.
Yahoo